Bone metastases are a serious complication across multiple cancers, significantly affecting patient quality of life. Patients may experience pain, fractures, spinal cord compression, reduced mobility and loss of independence, often diminishing dignity and increasing mortality risk. The condition most commonly affects the axial skeleton—the spine, pelvis and ribs—leading to severe complications.

Population-scale studies indicate that bone involvement affects 50–70% of patients with advanced breast or prostate cancer, while 15–40% of those with lung, kidney, thyroid and melanoma also develop skeletal metastases over time.

Zydus Lifesciences has been launching a wide range of biosimilars to treat various cancers ranging from breast cancer to prostate cancer, various other solid tumours and blood cancer. The company has also partnered with diagnostic companies.

Dr Sharvil P. Patel, Managing Director, Zydus Lifesciences, said, “With Denosumab 120 mg SC, we aim to bring access, affordability of medication in cancer patients needing critical care. This will help patients to retain mobility and support them in their fight against cancer.”

The Zydus Group, with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives.

Zydus Lifesciences reported a 38.12% jump in consolidated net profit to Rs 1,258.60 crore in Q2 FY26, compared with Rs 911.2 crore posted in Q2 FY25. Revenue from operations increased 18.07% year on year (YoY) to Rs 6,037.9 crore in Q2 FY26.